156 related articles for article (PubMed ID: 26908603)
1. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
2. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.
Bajenaru ML; Zhu Y; Hedrick NM; Donahoe J; Parada LF; Gutmann DH
Mol Cell Biol; 2002 Jul; 22(14):5100-13. PubMed ID: 12077339
[TBL] [Abstract][Full Text] [Related]
3. Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice.
Wozniak DF; Diggs-Andrews KA; Conyers S; Yuede CM; Dearborn JT; Brown JA; Tokuda K; Izumi Y; Zorumski CF; Gutmann DH
PLoS One; 2013; 8(6):e66024. PubMed ID: 23762458
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-induced glial IL-1β mediates extrinsic retinal ganglion cell vulnerability in murine Nf1 optic glioma.
Tang Y; Chatterjee J; Wagoner N; Bozeman S; Gutmann DH
Ann Clin Transl Neurol; 2024 Mar; 11(3):812-818. PubMed ID: 38229454
[TBL] [Abstract][Full Text] [Related]
5. NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.
Anastasaki C; Chatterjee J; Koleske JP; Gao Y; Bozeman SL; Kernan CM; Marco Y Marquez LI; Chen JK; Kelly CE; Blair CJ; Dietzen DJ; Kesterson RA; Gutmann DH
Neuro Oncol; 2024 Apr; ():. PubMed ID: 38607967
[TBL] [Abstract][Full Text] [Related]
6. Astrocyte responses to experimental glaucoma in mouse optic nerve head.
Quillen S; Schaub J; Quigley H; Pease M; Korneva A; Kimball E
PLoS One; 2020; 15(8):e0238104. PubMed ID: 32822415
[TBL] [Abstract][Full Text] [Related]
7. Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation.
de Andrade Costa A; Chatterjee J; Cobb O; Cordell E; Chao A; Schaeffer S; Goldstein A; Dahiya S; Gutmann DH
Neurooncol Adv; 2022; 4(1):vdab194. PubMed ID: 35187488
[TBL] [Abstract][Full Text] [Related]
8. Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.
Osum SH; Oribamise EI; Corbière SMAS; Taisto M; Jubenville T; Coutts A; Kirstein MN; Fisher J; Moertel C; Du M; Bedwell D; Largaespada DA; Watson AL
Mol Ther Nucleic Acids; 2023 Sep; 33():227-239. PubMed ID: 37520682
[TBL] [Abstract][Full Text] [Related]
9. MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma.
Ioannou M; Lalwani K; Ayanlaja AA; Chinnasamy V; Pratilas CA; Schreck KC
Mol Cancer Ther; 2024 May; ():. PubMed ID: 38714355
[TBL] [Abstract][Full Text] [Related]
10. Generation of a human iPSC line CIPi004-A from a patient with neurofibromatosis type 1 and epilepsy harboring a heterozygous mutation in NF1 gene.
Wu F; Ji X; Gao Y; Liu W; Lu Y; Yang A; Wang J; Chen Q; Zhang X
Stem Cell Res; 2024 May; 77():103444. PubMed ID: 38761686
[TBL] [Abstract][Full Text] [Related]
11. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis type 1.
Gutmann DH; Ferner RE; Listernick RH; Korf BR; Wolters PL; Johnson KJ
Nat Rev Dis Primers; 2017 Feb; 3():17004. PubMed ID: 28230061
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Molecular Characterization of NF1 Patients: Single-Center Experience of 32 Patients From China.
Zhu L; Zhang Y; Tong H; Shao M; Gu Y; Du X; Wang P; Shi L; Zhang L; Bi M; Wang X; Zhang G
Medicine (Baltimore); 2016 Mar; 95(10):e3043. PubMed ID: 26962827
[TBL] [Abstract][Full Text] [Related]
14. MRI Screening for Optic Gliomas in Neurofibromatosis Type 1.
Millichap JG
Pediatr Neurol Briefs; 2015 Sep; 29(9):72. PubMed ID: 26933608
[TBL] [Abstract][Full Text] [Related]
15. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
16. An Update on Neurofibromatosis Type 1: Not Just Café-au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer.
Hernández-Martín A; Duat-Rodríguez A
Actas Dermosifiliogr; 2016; 107(6):465-73. PubMed ID: 26956402
[TBL] [Abstract][Full Text] [Related]
17. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
18. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I.
Li K; Turner AN; Chen M; Brosius SN; Schoeb TR; Messiaen LM; Bedwell DM; Zinn KR; Anastasaki C; Gutmann DH; Korf BR; Kesterson RA
Dis Model Mech; 2016 Jul; 9(7):759-67. PubMed ID: 27482814
[TBL] [Abstract][Full Text] [Related]
19. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
Toonen JA; Ma Y; Gutmann DH
Neuro Oncol; 2017 Jun; 19(6):808-819. PubMed ID: 28039362
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
